Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$9.4M
3M shares
52-week range
$2.55 – $14.64
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.45%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.3K | $0 | $0 | $0 |
| Gross profit | −$1.3K | $0 | $0 | $0 |
| Gross margin | — | — | — | — |
| R&D | $392.9K | $4.1M | $4.2M | $4.1M |
| Operating income | −$2.7M | −$7.6M | −$11.0M | −$13.5M |
| EBITDA | −$6.6M | −$8.3M | −$10.6M | −$13.2M |
| Net income | −$6.7M | −$8.4M | −$10.7M | −$13.2M |
| Net margin | — | — | — | — |
| EPS (diluted) | -8.66 | -9.63 | -8.73 | -6.64 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-5.52 | $-7.74–$-4.01 | 2 |
| 2027 | $6M | $-3.42 | $-3.91–$-2.93 | 1 |
| 2028 | $17M | $-2.61 | $-2.89–$-2.33 | 2 |
| 2029 | $0 | $8.55 | $8.55–$8.55 | 1 |
Forward consensus · source: Financial Modeling Prep
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
www.cadrenal.comNo one on the platform currently holds CVKD.
No tracked institution reports a position in CVKD as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-08-20 | 1-for-15reverse |
No one on the platform has traded CVKD yet.
| $20M |
| — |
| NRSNNeuroSense Therapeutics Ltd. | $0.71 | -6.27% | $18M | — |
| NRXSNeurAxis, Inc. | $7.14 | -1.79% | $88M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CVKD #StockToWatch | $CVKD #CadrenalTherapeutics Breakthrough Moment in 2026 https://www.nasdaq.com/press-release/cadrenal-therapeutics-announces-selection-cad-1005-phase-2-study-late-breaking-oral #TheBullRunShow #AI #NASDAQ #NDAQ #wsj #nytimes #business #reuters #IHub_StockPosts #forbes #marketwatch #cnn #bet #foxnews #latimes
View on StockTwits ↗$CVKD: Discover the Future of HIT Treatment https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-selection-of-cad-1005-phase-2-study-5stbe42ry5n3.html #TheBullRunShow #CadrenalTherapeutics #CAD1005 #ISTH2026 #ClinicalResearch #Pharmaceuticals
View on StockTwits ↗$CVKD - Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement https://www.cadrenal.com/
View on StockTwits ↗$CVKD #CVKD Cadrenal Therapeutics, Inc. Phase 2 CAD-1005 study has been chosen for a late-breaking oral presentation at the ISTH 2026 Congress. https://www.nasdaq.com/press-release/cadrenal-therapeutics-announces-selection-cad-1005-phase-2-study-late-breaking-oral #CAD1005 #ISTH2026 #ClinicalTrials #ResearchNews #InnovativeTherapeutics @followers @topfans #TheBullRunShow
View on StockTwits ↗$CVKD Special News | #CVKD Cadrenal Therapeutics said its CAD-1005 Phase 2 study has been chosen for a late-breaking oral presentation at the ISTH 2026 Congress. https://www.nasdaq.com/press-release/cadrenal-therapeutics-announces-selection-cad-1005-phase-2-study-late-breaking-oral #TheBullRunShow #Cadrenal #CAD1005 #ISTH2026 #ClinicalTrials #HealthcareInnovation @MikeTechnician @LadonnaKelly @SaraWelch @OnTheBalance @BioTuesdays @EfamhS
View on StockTwits ↗$CVKD Breaking News : Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-selection-cad-120000124.html
View on StockTwits ↗$CVKD - announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation. The announcement comes ahead of the BIO International Convention, June 22–25, 2026, in San Diego, California. Cardenal's executive leadership team will highlight this rare pediatric initiative and its Phase 3-ready CAD-1005 platform during one-on-one partnering meetings with global and regional pharmaceutical companies.
View on StockTwits ↗$CVKD Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html
View on StockTwits ↗$CVKD Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html
View on StockTwits ↗$CVKD Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html $SNDK
View on StockTwits ↗$CVKD Stop Spamming other boards... first sign of a liquidity seeking SCAM
View on StockTwits ↗@JuanitaWilsona Scam Spam Report and Block $CVKD must be garbage to be constantly and desperately spamming for liquidity... seriously won't look at it because of the never ending spamming. GTFO 🤣
View on StockTwits ↗$CVKD intends to file for #FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki Disease. https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html #TheBullRunShow #CVKD #CadrenalTherapeutics #FDA #RarePediatricDisease #KawasakiDisease #Tecarfarin #Biotech #HealthcareStocks #BiotechStocks #NASDAQ #HealthcareInvesting #BiotechStocks #PennyStocks #StockMarket #GrowthStocks #Investing #SmallCapStocks #EmergingBiotech #HealthcareStocks #LifeSciences #ShareholderValue #MedicalBreakthrough 🚀📈
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.